News

  • Notice of Information of Intent to Publish Research Opportunity Announcements for the “NeuroNEXT Clinical Trials: Stage 1 (Preliminary) and Stage 2 (Protocol) Applications (OT2)”

    NOI for 2 new ROAs will be issued for NeuroNEXT Clinical Trials: Stage 1 Preliminary Application and Stage 2 Protocol Application will replace the current Notice of Funding Opportunity ‘NeuroNEXT Clinical Trials (U01 Clinical Trial Optional) PAR-21-223’ expiring on March 06, 2024. NOI: https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-045.html

  • Gene Therapy Consortium ROAs Published

    The ROAs for the Gene Therapy Consortium were published on December 4, 2023.  Please find the links below.  The submissions will be accepted starting on December 28, 2023 and the submission deadline is rolling. https://www.ninds.nih.gov/sites/default/files/documents/URGenT%20CT%20NN%20ROA%20Stage1_clean_508C.pdf https://www.ninds.nih.gov/sites/default/files/documents/URGenT%20CT%20NN%20ROA%20Stage2_clean_508C.pdf

  • Dr. Rossignol to Present as Part of 2022 GNEM Symposium Speaker Series

    Dr. Francis Rossignol of hte NIH National Human Genome Research Institute (NHBRI) will present as part of theGNEM Symposium Speaker Series presented by the Neuromuscular Disease Foundation. His talk, entitled “ManNAc As A Potential Therapy for GNE Myopathy – Advances and Future Directions” will include discussion of NN109. This talk is free of charge and available virtually. More information…

  • Network Renewal RFAs Posted!

    The RFAs for the network renewal were published on September 20, 2022. Please find links below. The deadline for grant submissions is November 21, 2022. Please note that there has been a notice of correction published related to the site RFA: https://grants.nih.gov/grants/guide/notice-files/NOT-NS-23-028.html

  • NN106 Cyto-C Clinical Trial Prospective Biomarker Study Results Published

    NN106 CYTO-C Prospective biomarker study results have been published in Neurooncology Advances.  

  • NN103 (BeatMG) Study Results Cited in NeurologyLive

    Results of the NN103 study were cited in NeurologyLive.  

  • NN103 Primary Results published in Neurology

    The results of the NN103 Beat MG have been posted online at the American Academy of Neurology.  

  • Dixie Ecklund named to Society for Clinical Trials Class of 2021 Fellows

    Congratulations to Dixie Ecklund, Director of Operations at the NeuroNEXT DCC, for being selected to join the Society for Clinical Trials Class of 2021 Fellows! Ecklund will be recognized as a new inductee at the virtual SCT annual meeting in May.

  • NeuroNEXT Fellow and CTMC Alum highlighted at Wake Forest CTSI

    A NeuroNEXT Fellowship can help young neurology faculty develop their careers, as highlighted by Wake Forest University in an article about former NeuroNEXT Fellow and Clinical Trials Methodology Course (CTMC) alumnus Dr. Heidi Munger Clay (see link below).

  • CTMC: 2021 Call for Applications

    We are pleased to announce that the NINDS Clinical Trials Methodology Course (CTMC) is accepting applications for the 2021 cohort. The overarching goal of the CTMC is to help investigators develop scientifically rigorous, yet practical clinical trial protocols. Our focus is on investigators who have not previously designed their own prospective, interventional clinical trials.    Course:  Due to…